Ignite Creation Date:
2024-05-05 @ 5:08 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00394173
Status:
COMPLETED
Last Update Posted:
2017-02-27
First Post:
2006-10-30
Brief Title:
Efficacy Safety and Tolerability of DNK333 25 mg Bid in Women With Diarrhea-predominant Irritable Bowel Syndrome IBS-D
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Parallel-group Multicenter Study to Evaluate the Efficacy and Safety of DNK333 25mg bid Given Orally for 4 Weeks in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome IBS-D
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy of DNK333 compared to placebo for relieving symptoms of IBS-D in female patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None